WO1999055333A1 - Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses - Google Patents
Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses Download PDFInfo
- Publication number
- WO1999055333A1 WO1999055333A1 PCT/FR1999/000973 FR9900973W WO9955333A1 WO 1999055333 A1 WO1999055333 A1 WO 1999055333A1 FR 9900973 W FR9900973 W FR 9900973W WO 9955333 A1 WO9955333 A1 WO 9955333A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metronidazole
- econazole
- pharmaceutical composition
- salts
- clotrimazole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
Definitions
- the present invention relates to a pharmaceutical composition for the empirical treatment of infectious vulvovaginitis and vaginosis.
- the empirical treatment of these conditions consists in immediately prescribing a pharmaceutical composition on the sole basis of clinical examination, without waiting for the results of a bacteriological laboratory analysis which would make it possible to precisely determine the germ (s) involved in the condition studied. .
- compositions prescribed comprise an active ingredient alone or a combination of several active ingredients taking into account the diversity of the germs responsible for these conditions.
- this combination combines a broad-spectrum antifungal such as nystatin with one or more antibiotics such as polymyxin or neomycin.
- One of the aims of the invention is to propose a pharmaceutical composition suitable for the empirical local treatment of infectious vulvovaginitis and vaginosis, having an efficacy greater than the associations already proposed and devoid of the drawbacks of the latter (it is acts of a treatment of the simple, not complicated, local affections, requiring only a purely local treatment).
- the composition of the invention comprises a combination of at least two imidazole derivatives exhibiting a reinforcing synergy (potentiation) with respect to the germs responsible for infectious vulvovaginitis and vaginosis and chosen from the group comprising metronidazole, l econazole, miconazole, clotrimazole, terconazole, bifonazole, cloconazole, isoconazole, oxiconazole, sulconazole, tioconazole and their salts, preferably the group comprising metronidazole, econazole, miconazole, clotrimazole, terconazole and their salts, and with the exception of metronidazole combined with miconazole, tioconazole or clotrimazole.
- one of the imidazole derivatives is metronidazole and the other is chosen from the group comprising econazole, clotrimazole, terconazole, bifonazole, cloconazole, isoconazole, oxiconazole, sulconazole and their salts, preferably the group comprising econazole, clotrimazole, terconazole and their salts, very preferably econazole and its salts.
- the composition comprises metronidazole and econazole nitrate at a total daily dose of 250 to 1050 mg, the ratio of metronidazole / econazole nitrate doses being able to 3
- the imidazole derivatives are preferably in suspension in a lipophilic phase comprising as excipients a lipophilic agent, a water-dispersible agent and a bioadhesive agent, for example a lipophilic phase formulated, for a daily dose, at : micronized econazole nitrate, 150 mg; micronized metronidazole, 500 mg; hydroxypropylcellulose, 20 mg; PEG-7 glyceryl co-coate, 20 mg; silicone oil, 1560 mg.
- a particularly advantageous dosage form is that of a hard or soft capsule comprising a hard or soft solid outer envelope containing gelatin, enclosing a non-aqueous liquid or semi-liquid internal phase comprising the lipophilic phase.
- - econazole has a dual activity, antifungal against Candida albicans and non-albicans, and antibacterial in particular on the main Gram + bacteria responsible for episodes of superinfection of vulvovaginal yeast infections (the imbalance of the vaginal ecosystem caused by a mycosis can indeed favor the pathogenic development of certain Gram + saprophytic germs of the vaginal environment such as Staphylococcus aureus, Strepto- 4
- each test cup is subcultured on an agar medium suitable for confirming the visual reading of the development of the microorganisms.
- the moderate presence of microorganisms can be observed in wells where no microbial development is visible: the microorganisms brought in at the start of the test are not developed but have remained alive; this is indeed an inhibition.
- the subculturing of the wells therefore makes it possible to confirm the visual reading of the results and also to distinguish the bactericidal concentrations from the inhibiting concentrations. 5
- the MIC was also determined on a strain of Propionibacterium acnes CIP 53 117 T incubated anaerobically. The results are as follows: - 2.41 mg / ml for metronidazole alone,
- the activity of the mixture is only due to the presence of econazole nitrate, but the presence of metronidazole in the mixture does not create any antagonism capable of affecting the antifungal or antimicrobial activity of econazole nitrate.
- Lactobacillus acidophilus and Lactobacillus crispatus are non-pathogenic germs existing physiologically in the vaginal flora, and which should be preserved.
- a tolerance study was also carried out versus placebo on rabbits to assess the presence of erythema or edema indicative of possible irritation, as well as body weight and food consumption.
- the combination studied thus has a tolerance equal to that of placebo, without any irritant effect or incidence of the treatment on the weight of the animals, which would tend to establish the absence of systemic toxicity of the combination.
- the two active ingredients are combined with an excipient comprising a lipophilic phase (fatty phase).
- This lipophilic phase in addition to its compatibility with the two active ingredients, must be able to promote homogenization with vaginal secretions by providing a certain hydrophilic character and, on the other hand, provide bioadhesion to avoid as much as possible the flow phenomena.
- the hydrophilic bioadhesive agent gels, and the dosage form emulsifies thanks to the presence of the water-dispersible agent, which allows in particular a direct passive diffusion of the active principle between the emulsified excipient and the vaginal mucosa with which it is in contact.
- the bioadhesive (more precisely, mucoadhesive) nature of the hydrophilic gelling agent makes it possible to make the emulsion sticky on the mucosa, with a low flow, thus providing a long-term maintenance.
- This long-term maintenance makes it possible in particular to space out the administrations, which may be only daily.
- the lipophilic phase thus comprises a lipophilic agent, a water-dispersible agent and a bioadhesion agent.
- the lipophilic agent can be a silicone oil such as a dimethylpolysiloxane of the Dimethicone 100 type, in accordance with the French pharmacopoeia tenth edition and the European pharmacopoeia third edition; its viscosity is between 50.10 "6 and 150.10 " 6 m 2 / s (50 and 150 centistokes).
- cocoa butter Carnauba wax
- solid hemisynthetic triglycerides type AIML Supepocire or Witepsol H 15
- triglycerides of coconut oil fatty acids type Softisan® 378
- liquid triglycerides type Miglyol 812).
- the water-dispersible agent can be chosen from: polyoxyethylene glycol 7-glyceryl-cocoate (cetiol HE type), fatty acid esters or 8
- the bioadhesion agent can be chosen from: hydroxypropylcellulose (Klucel® HXF type), carboxyvinyl acids, carboxymethylcellulose, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, carob gum, xanthan gum, guar gum, aluminum silicate , carrageenans.
- a typical example of the formulation of an oily phase is:
- This fatty phase has a dynamic viscosity of the order of 10,000 mPa.s ⁇ 20%. It can be incorporated into a wide variety of dosage forms for local administration such as soft capsule, capsule, egg, single-dose applicator, sachet, or tube.
- Silicone oil (Diméticone® 100): 0 to 25%, i.e. 0 to 327.5 mg
- Solid triglycerides (Suppocire® AIML) q. s. 2000 mg
- Example 3 soft capsule, sachet or single dose
- the dosage form called "soft capsule” is, as far as it is well known, with an initially solid external phase - therefore easy to handle and to set up - comprising gelatin, in particular consisting of gelatin and glycerin, enclosing an internal liquid or semi-liquid phase containing a therapeutic agent.
- gelatin in particular consisting of gelatin and glycerin
- EP-A-0 121 321 describes a soft capsule comprising an active principle dissolved or in suspension and a composition preventing the embrittlement of the soft capsule.
- the internal phase of which the formulation has been given above is introduced once prepared in an external envelope comprising gelatin, in particular an external envelope of gelatin / glycerin corresponding to a structure known under the name of "soft capsule". It will be noted that the above formulation brings a certain hydrophilic character to the internal fatty phase (to promote homogenization with vaginal secretions), but that this hydro- 10
- phile remains compatible with the external phase comprising gelatin so as not to denature it (otherwise the capsule would melt by itself before even being used).
- Hydroxypropylcellulose (Klucel ® HXF) 20 mg Carboxyvinylic acid (Carbopol® 974 P) 50 mg
- Example 7 sachet for aqueous suspension
- Microcrystalline cellulose (Avicel® RC) 40 mg
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002329762A CA2329762A1 (fr) | 1998-04-24 | 1999-04-23 | Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses |
JP2000545531A JP2002512961A (ja) | 1998-04-24 | 1999-04-23 | 外陰膣炎および膣症を局所的に治療するための医薬品イミダゾールの併用 |
EP99915828A EP1071421A1 (fr) | 1998-04-24 | 1999-04-23 | Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses |
AU34271/99A AU3427199A (en) | 1998-04-24 | 1999-04-23 | Pharmaceutical imidazole combination for locally treating vulvovaginitis and vaginosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR98/05174 | 1998-04-24 | ||
FR9805174A FR2777783A1 (fr) | 1998-04-24 | 1998-04-24 | Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999055333A1 true WO1999055333A1 (fr) | 1999-11-04 |
Family
ID=9525649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/000973 WO1999055333A1 (fr) | 1998-04-24 | 1999-04-23 | Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1071421A1 (fr) |
JP (1) | JP2002512961A (fr) |
AU (1) | AU3427199A (fr) |
CA (1) | CA2329762A1 (fr) |
FR (1) | FR2777783A1 (fr) |
WO (1) | WO1999055333A1 (fr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002087570A1 (fr) * | 2001-05-01 | 2002-11-07 | Mcneil-Ppc, Inc. | Composition comprenant des agents antifongiques pour le traitement de la vulvovaginite et de la vaginose |
JP2005523239A (ja) * | 2001-10-02 | 2005-08-04 | キンバリー クラーク ワールドワイド インコーポレイテッド | 芳香族化合物を用いるエキソプロテイン産生の抑制 |
WO2005087270A1 (fr) * | 2004-03-10 | 2005-09-22 | Edko Trading And Representation Co. Ltd. | Compositions anti-vaginite comprenant un triazole |
GB2412317A (en) * | 2004-03-23 | 2005-09-28 | Mcneil Ppc Inc | Solid dosage form for treatment of infections of a body cavity, especially bacterial and fungal infections of the vaginal cavity |
CN105982876A (zh) * | 2015-01-27 | 2016-10-05 | 深圳市佳泰药业股份有限公司 | 硝酸益康唑阴道软胶囊及其制备方法 |
US10675288B2 (en) | 2011-11-23 | 2020-06-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10888516B2 (en) | 2012-12-21 | 2021-01-12 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11103513B2 (en) | 2014-05-22 | 2021-08-31 | TherapeuticsMD | Natural combination hormone replacement formulations and therapies |
US11103516B2 (en) | 2011-11-23 | 2021-08-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2021257179A1 (fr) * | 2020-06-18 | 2021-12-23 | National Medical Supply, LLC | Gel vaginal |
US11241445B2 (en) | 2012-12-21 | 2022-02-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8309103B2 (en) * | 2004-01-22 | 2012-11-13 | Alparis, S.A. De C.V. | Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007325A1 (fr) * | 1988-12-30 | 1990-07-12 | Edko Trading And Representation Company Limited | Pessaire contenant des medicaments antibacteriens |
WO1993025238A1 (fr) * | 1992-06-08 | 1993-12-23 | Schering-Plough Healthcare Products, Inc. | Compositions de poudres antifongiques stables contenant de l'imidazole |
EP0770384A1 (fr) * | 1995-10-27 | 1997-05-02 | Montefarmaco S.p.A. | Compositions solides, anhydres et pharmaceutiques pour utilisation vaginale |
WO1997044032A1 (fr) * | 1996-05-17 | 1997-11-27 | Edko Trading And Representation Company Limited | Compositions contre la vaginite pour utilisation topique comprenant un ou plusieurs medicaments contre la vaginite et un ou plusieurs anesthesiques locaux |
-
1998
- 1998-04-24 FR FR9805174A patent/FR2777783A1/fr not_active Withdrawn
-
1999
- 1999-04-23 AU AU34271/99A patent/AU3427199A/en not_active Abandoned
- 1999-04-23 WO PCT/FR1999/000973 patent/WO1999055333A1/fr not_active Application Discontinuation
- 1999-04-23 JP JP2000545531A patent/JP2002512961A/ja active Pending
- 1999-04-23 EP EP99915828A patent/EP1071421A1/fr not_active Withdrawn
- 1999-04-23 CA CA002329762A patent/CA2329762A1/fr not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007325A1 (fr) * | 1988-12-30 | 1990-07-12 | Edko Trading And Representation Company Limited | Pessaire contenant des medicaments antibacteriens |
WO1993025238A1 (fr) * | 1992-06-08 | 1993-12-23 | Schering-Plough Healthcare Products, Inc. | Compositions de poudres antifongiques stables contenant de l'imidazole |
EP0770384A1 (fr) * | 1995-10-27 | 1997-05-02 | Montefarmaco S.p.A. | Compositions solides, anhydres et pharmaceutiques pour utilisation vaginale |
WO1997044032A1 (fr) * | 1996-05-17 | 1997-11-27 | Edko Trading And Representation Company Limited | Compositions contre la vaginite pour utilisation topique comprenant un ou plusieurs medicaments contre la vaginite et un ou plusieurs anesthesiques locaux |
Non-Patent Citations (6)
Title |
---|
BIOLOGICAL ABSTRACTS, vol. 84, 1987, Philadelphia, PA, US; abstract no. 000084043796, FARAH C A ET AL: "TINIDAZOLE-TIOCONAZOLE COMBINATION IN THE TREATMENT OF VAGINAL INFECTION DUE TO TRICHOMONAS GARDNERELLA-VAGINALIS OR CANDIDA-ALBICANS" XP002091996 * |
BIOLOGICAL ABSTRACTS, vol. 85, 1987, Philadelphia, PA, US; abstract no. 000085013398, GONCALVES N M C: "CLINICAL EVALUATION OF A SALICYLIC ACID-BORIC ACID-AMMONIUM ALUM COMBINATION AS COADJUVANTS IN THE TREATMENT OF TRICHOMONAS-VAGINALIS AND CANDIDA-ALBICANS VULVOVAGINITIS" XP002091995 * |
BIOLOGICAL ABSTRACTS, vol. 98, 1996, Philadelphia, PA, US; abstract no. 199698787802, DEBBIA E A: "In vitro activity of metronidazole alone and in combination with clotrimazole against clinical isolates of Trichomonas vaginalis." XP002091994 * |
J BRAS GINECOL, vol. 97, no. 1-2, 1987, pages 43-47 * |
J BRAS GINECOL, vol. 97, no. 7, 1987, pages 359 - 362 * |
JOURNAL OF CHEMOTHERAPY, 1996, vol. 8, no. 2, 1996, pages 96 - 101 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002087570A1 (fr) * | 2001-05-01 | 2002-11-07 | Mcneil-Ppc, Inc. | Composition comprenant des agents antifongiques pour le traitement de la vulvovaginite et de la vaginose |
JP2005523239A (ja) * | 2001-10-02 | 2005-08-04 | キンバリー クラーク ワールドワイド インコーポレイテッド | 芳香族化合物を用いるエキソプロテイン産生の抑制 |
WO2005087270A1 (fr) * | 2004-03-10 | 2005-09-22 | Edko Trading And Representation Co. Ltd. | Compositions anti-vaginite comprenant un triazole |
EA011952B1 (ru) * | 2004-03-10 | 2009-06-30 | Эдко Трейдинг Энд Репрезентейшн Ко. Лтд. | Противовагинитные композиции, содержащие триазол |
GB2412317A (en) * | 2004-03-23 | 2005-09-28 | Mcneil Ppc Inc | Solid dosage form for treatment of infections of a body cavity, especially bacterial and fungal infections of the vaginal cavity |
US11103516B2 (en) | 2011-11-23 | 2021-08-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11793819B2 (en) | 2011-11-23 | 2023-10-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10675288B2 (en) | 2011-11-23 | 2020-06-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11110099B2 (en) | 2012-06-18 | 2021-09-07 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11529360B2 (en) | 2012-06-18 | 2022-12-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11166963B2 (en) | 2012-06-18 | 2021-11-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11123283B2 (en) | 2012-12-21 | 2021-09-21 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11622933B2 (en) | 2012-12-21 | 2023-04-11 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11116717B2 (en) | 2012-12-21 | 2021-09-14 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11304959B2 (en) | 2012-12-21 | 2022-04-19 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10888516B2 (en) | 2012-12-21 | 2021-01-12 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10835487B2 (en) | 2012-12-21 | 2020-11-17 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11351182B2 (en) | 2012-12-21 | 2022-06-07 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11065197B2 (en) | 2012-12-21 | 2021-07-20 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11241445B2 (en) | 2012-12-21 | 2022-02-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11497709B2 (en) | 2012-12-21 | 2022-11-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11103513B2 (en) | 2014-05-22 | 2021-08-31 | TherapeuticsMD | Natural combination hormone replacement formulations and therapies |
CN105982876A (zh) * | 2015-01-27 | 2016-10-05 | 深圳市佳泰药业股份有限公司 | 硝酸益康唑阴道软胶囊及其制备方法 |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
WO2021257179A1 (fr) * | 2020-06-18 | 2021-12-23 | National Medical Supply, LLC | Gel vaginal |
US11529346B2 (en) | 2020-06-18 | 2022-12-20 | National Medical Supply, LLC | Vaginal gel |
Also Published As
Publication number | Publication date |
---|---|
AU3427199A (en) | 1999-11-16 |
CA2329762A1 (fr) | 1999-11-04 |
JP2002512961A (ja) | 2002-05-08 |
FR2777783A1 (fr) | 1999-10-29 |
EP1071421A1 (fr) | 2001-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999055333A1 (fr) | Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses | |
EP2395998B1 (fr) | Association de l'ivermectine avec la brimonidine pour le traitement ou la prévention de la rosacee | |
US6420425B1 (en) | Method for the broad based treatment of infections especially infections of organs such as the skin and vagina | |
US20030017207A1 (en) | Compositions and methods for treating vulvovaginitis and vaginosis | |
AU2009202927A1 (en) | Warming and nonirritating lubricant antifungal gel compositions | |
EP1754481A2 (fr) | Utilisation d' agents antifongiques pour traiter l'otite externe | |
RU2306133C2 (ru) | Согревающие и нераздражающие смазывающие противогрибковые гелеобразные композиции | |
CN111601585B (zh) | 用于治疗粘膜感染的乳剂 | |
EP2165704B1 (fr) | Utilisation de l'alvérine dans le traitement des affections cutanées | |
EP0253037B1 (fr) | Composition inhibitrice d'au moins un être vivant unicellulaire et/ou virus, procédé de fabrication et applications de cette composition | |
EP2505192B1 (fr) | Utilisation d'excipients en tant que conservateurs et composition pharmaceutique les comprenant | |
EP0310476B1 (fr) | Composition inhibitrice ou destructrice d'au moins un être vivant unicellulaire renfermant du fluor F- et du lithium Li+ | |
FR2989279A1 (fr) | Utilisation de l'acide cinnamique pour prevenir ou traiter des infections provoquees par un antigene resistant ou une combinaison d'antigenes | |
FR2872702A3 (fr) | Systeme de delivrance | |
JPWO2002098463A1 (ja) | 抗真菌組成物 | |
Ignacio et al. | Comparative analysis of antifungal activity of natural remedies versus miconazole nitate salt against Candida albicans | |
WO2018051363A1 (fr) | Formulations antifongiques préparées à partir de plantes médicinales pour la candidose vaginale | |
FR2609714A1 (fr) | Compositions liquides stables a base de derives antifongiques imidazoles | |
AU2002309593A1 (en) | Composition comprising antifungal agents for treating vulvovaginitis and vaginosis | |
FR3064179A1 (fr) | Agent conservateur contenant de l'hinokitiol avec au moins un acide et compositions preservees par ledit agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999915828 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2329762 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09673237 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999915828 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999915828 Country of ref document: EP |